Net Cash Provided by (Used in) Operating Activities in USD of RELMADA THERAPEUTICS, INC. from Q4 2012 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
RELMADA THERAPEUTICS, INC. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and change rate from Q4 2012 to Q1 2025.
  • RELMADA THERAPEUTICS, INC. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2025 was -$18.1M, a 38.6% decline year-over-year.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$51.8M, a 0.19% decline from 2023.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$51.7M, a 50.2% increase from 2022.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$104M, a 13% decline from 2021.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$18.1M -$5.03M -38.6% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q1 2024 -$13M +$3.47M +21% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q1 2023 -$16.5M +$2.92M +15.1% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q1 2022 -$19.4M -$3.34M -20.8% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q1 2021 -$16.1M -$12.7M -370% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q1 2020 -$3.42M -$1.41M -70.2% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q3 2019 -$2.53M -$863K -51.7% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2019
Q1 2019 -$2.01M 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q3 2018 -$1.67M -$692K -70.7% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q3 2017 -$979K +$1.17M +54.3% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q3 2016 -$2.14M +$1.07M +33.3% 01 Jul 2016 30 Sep 2016 10-Q 10 Nov 2016
Q3 2015 -$3.22M -$894K -38.5% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q3 2014 -$2.32M -$1.91M -468% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015
Q1 2014 -$1.02M -$617K -154% 01 Jan 2014 31 Mar 2014 8-K 27 May 2014
Q4 2013 -$9.12K* -$10.6K 01 Sep 2013 30 Nov 2013 10-Q 13 Jan 2014
Q3 2013 -$409K 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014
Q1 2013 -$400K 01 Jan 2013 31 Mar 2013 8-K 27 May 2014
Q4 2012 $1.5K* 01 Sep 2012 30 Nov 2012 10-Q 13 Jan 2014

RELMADA THERAPEUTICS, INC. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$51.8M -$96.6K -0.19% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 -$51.7M +$52.1M +50.2% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 -$104M -$11.9M -13% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024
2021 -$91.9M -$64.1M -230% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023
2020 -$27.8M -$15.7M -130% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
2019 -$12.1M -$6.09M -101% 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021
2018 -$6M +$464K +7.18% 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020
2017 -$6.47M +$6.68M +50.8% 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018
2016 -$13.1M +$3.08M +19% 01 Jul 2015 30 Jun 2016 10-K 28 Sep 2017
2015 -$16.2M 01 Jul 2014 30 Jun 2015 10-K 09 Sep 2016
2013 -$2.24M -$654K -41.3% 01 Jan 2013 31 Dec 2013 10-K 11 Sep 2015
2012 -$1.58M 01 Jan 2012 31 Dec 2012 10-KT 09 Sep 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.